Navigation Links
Insmed to Appeal Delisting Notification From Nasdaq
Date:12/26/2007

RICHMOND, Va., Dec. 26 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today announced that it has requested a hearing before a Nasdaq Listing Qualifications Panel to appeal an earlier Staff Determination to delist the Company's common stock from the Nasdaq Global Market.

Insmed received a letter from the Nasdaq Stock Market ("Nasdaq") on December 20, 2007 indicating that the Company has failed to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share for continued listing of the Company's common stock on the Nasdaq Global Market as set forth in Marketplace Rule 4450(a)(5) (the "Staff Determination"). As a result, the Company's common stock is subject to be delisted from the Nasdaq Global Market on December 31, 2007. Following procedures set forth in the Nasdaq Marketplace Rule 4800 series, Insmed has requested a hearing before a Nasdaq Listing Qualifications Panel (the "Panel") to review the Staff Determination. The hearing request will stay the delisting of the Company's common stock, pending the decision of the Panel, allowing it to continue to trade on the Nasdaq Global Market. There can be no assurance however, that the Panel will grant Insmed's request for continued listing on the Nasdaq Global Market.

In the event that the Panel denies the Company's request for continued listing on the Nasdaq Global Market, the Company's common stock could be eligible to trade on the Nasdaq Capital Market or the OTC Bulletin Board.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursua
'/>"/>

SOURCE Insmed Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Insmed Appoints Dennis M. Lanfear to Board Of Directors
2. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
3. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
4. XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market
5. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
6. Biomira Inc. receives Nasdaq delisting notification
7. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
8. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
9. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
10. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
11. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...ov.24/PRNewswire-FirstCall/--NeurogesX,Inc.(Nasdaq...ingandcommercializingnovelpainmanagementtherapies,...ExecutiveOfficer,isscheduledtopresentatthe21stAnnu...r1-2,2009atTheNewYorkPalaceHotelinNewYork,NewYork....lOfficer,willbeavailabletorespondtoquestionsduring...
(Date:11/24/2009)...Newswire/--BlueMarbleEnergyCorp.announcedtodaythat...PDA)wererecentlyawarded$2millionbyWashingtonState,...ate/publicpartnershiptoconstructthestate,sfirstspe..., "Thisinvestmentwillsignificantlyspeedthedevelo...olnCounty,"saidBlueMarbleEnergyCEOKellyOgilvie."We...
(Date:11/24/2009)...dpointhasbeenmetforpatientswithadvanced-stage,orre.../PRNewswire-FirstCall/-AEternaZentarisInc.(NASDAQ:...icalcompanyfocusedonendocrinetherapyandoncology,to...thitstargetedcytotoxicpeptideconjugate,AEZS-108(fo...ometrialcancer.Inapersonalizedhealthcareapproach,t...
(Date:11/24/2009).../PRNewswire-FirstCall/--Shireplc(LSE:SHP,NASDAQ: ...,today,announcedthatithassubmittedaMAAtotheEuropea...enzymereplacementtherapyindevelopment,forthetreatm...pplicationforvelaglucerasealfathathasbeensubmitted...a. , Basedonaglobalsupplyshortageofthecurrent...
Breaking Biology Technology:NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3
...Nov. 12 AMDL, Inc. (Amex:,ADL), a vertically inte...hina and the US, announced today preliminary third...ation., For the third quarter of FY2008, AMDL exp... and net sales after sales promotions of,approxima...approximately,$4.9 million and income from operati...
...Nov. 12 Novavax, Inc.,(Nasdaq: NVAX ) a clinical...ahul Singhvi, President and Chief Executive Office...s 5th Annual Healthcare Conference at 3:00 pm.,(ES...w York city. Dr.,Singhvi will provide an overview ...t progress. A link to the live presentation can be...
...alia, Nov. 12 Phosphagenics,Limited ("Phosphagenic...it,has initiated a phase 1 human clinical trial us...e targeted delivery of a leading non steroidal,ant... will compare the,bioavailability and penetration ...fenac), one of the leading marketed products, and ...
Other Biology Technology:AMDL Announces Preliminary Third Quarter Earnings; Revises 2008 Guidance 2AMDL Announces Preliminary Third Quarter Earnings; Revises 2008 Guidance 3Transdermal Diclofenac enters Phase 1 Clinical Trial in Humans 2
(Date:11/24/2009)... Spanish . , The presence of increased body ...ubstances in the blood, hinders the loss and maint...ect of the University of Navarra conducted by Estb... Pharmacy. , The project, entitled "A nutrigenet...ol of body weight and inflammation," examines how ...
(Date:11/23/2009)... The time of day matters to forest trees dealing w...a research team led by Professor Malcolm Campbell,...l for research and colleagues in the department of.... , Capitalizing on their previous work to dec...am examined how poplar trees use their 45,000 gene...
(Date:11/23/2009)... provides "incontrovertible evidence" that the vol...tra about 73,000 years ago deforested much of cent...searchers report. , The volcano ejected an estim...re, leaving a crater (now the world,s largest volc...meters wide. Ash from the event has been found in ...
Breaking Biology News(10 mins):It can be predicted the reaction obese patients will have to a diet 2Time of day matters to thirsty trees, U of T researcher discovers 2Supervolcano eruption -- in Sumatra -- deforested India 73,000 years ago 2Hard To Treat Diseases 28HTDS PK 29 Thailand Registration 52304 1Hard To Treat Diseases 28HTDS PK 29 Thailand Registration 52304 2Columbia leads national effort to develop early intervention for schizophrenia 52300 1Columbia leads national effort to develop early intervention for schizophrenia 52300 2Columbia leads national effort to develop early intervention for schizophrenia 52300 3 242 million grant aids study of lung cancer in people who never smoked 9305 1 242 million grant aids study of lung cancer in people who never smoked 9305 2 242 million grant aids study of lung cancer in people who never smoked 9305 3
... , The largest living structures on Earth and the...e at risk, the most definitive review yet of the i...s concluded. , In a paper published in the presti...ientists reveal that world leaders face a race aga... communities dependent upon them for the inevitabl...
...-- A pioneering study of wild chimpanzees has foun...y experience menopause, rebutting previous studies...female chimpanzees reach reproductive senescence a...ata from wild gorillas and orangutans, the finding...logy -- suggests that human females are rare or ev...
...searchers from the University of Pennsylvania and ...ason why one of the most commonly activated protei...re Genetics this week, the Myc protein can stop th...s of nucleic acid that help control which genes ar...tances, re-introducing repressed miRNAs ,into Myc-...
Other Biology News:It's official: The carbon crisis is lethal for coral reefs 2It's official: The carbon crisis is lethal for coral reefs 3It's official: The carbon crisis is lethal for coral reefs 4Wild chimpanzees appear not to regularly experience menopause 2University of Pennsylvania researchers zero in on the tiniest members in the war on cancer 2
I-SAGE Ditag PCR Module* from Invitrogen
Captivate disposable sample chamber - for Captivate magnetic yoke - set of 10 from Molecular Probes (Invitrogen)
Custom Human Cytokine Antibody Array, Choose from hundreds of proteins. from Raybiotech, Inc.
I-SAGE Kit without magnetic stand from Invitrogen
Biology Products: